What is HC Wainwright’s Forecast for CRBP FY2029 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects that the biopharmaceutical company will earn ($3.56) per share for the year. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share.

Several other analysts also recently weighed in on the company. Piper Sandler initiated coverage on Corbus Pharmaceuticals in a research note on Monday, December 2nd. They set an “overweight” rating and a $35.00 target price on the stock. Wedbush restated an “outperform” rating and set a $51.00 price objective on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. Finally, StockNews.com upgraded shares of Corbus Pharmaceuticals to a “sell” rating in a research report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $61.38.

Corbus Pharmaceuticals Trading Up 5.1 %

Shares of NASDAQ CRBP opened at $9.48 on Wednesday. Corbus Pharmaceuticals has a 12-month low of $8.50 and a 12-month high of $61.90. The company has a market cap of $115.47 million, a PE ratio of -2.02 and a beta of 2.63. The stock has a 50 day simple moving average of $12.19 and a 200-day simple moving average of $26.21.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several large investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Corbus Pharmaceuticals during the third quarter valued at approximately $151,000. abrdn plc increased its holdings in shares of Corbus Pharmaceuticals by 422.9% in the third quarter. abrdn plc now owns 26,894 shares of the biopharmaceutical company’s stock valued at $555,000 after buying an additional 21,751 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Corbus Pharmaceuticals by 29.9% during the 3rd quarter. Victory Capital Management Inc. now owns 24,760 shares of the biopharmaceutical company’s stock valued at $511,000 after acquiring an additional 5,700 shares during the last quarter. HealthInvest Partners AB boosted its stake in shares of Corbus Pharmaceuticals by 77.9% during the 3rd quarter. HealthInvest Partners AB now owns 69,573 shares of the biopharmaceutical company’s stock worth $1,435,000 after acquiring an additional 30,473 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Corbus Pharmaceuticals by 224.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company’s stock worth $1,932,000 after acquiring an additional 64,800 shares during the last quarter. Institutional investors own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.